Resamirigene bilparvovec
Resamirigene Bilparvovec is a gene therapy product developed for the treatment of Leber's congenital amaurosis (LCA), a rare genetic disorder affecting the retina at the back of the eye. It is the first gene therapy approved for a genetic disease in the United States by the Food and Drug Administration (FDA).
Overview
Resamirigene Bilparvovec, also known as Luxturna, is a novel gene therapy that introduces a normal copy of the RPE65 gene into retinal cells. The RPE65 gene is responsible for producing a protein that makes light perception possible in the eyes. Mutations in this gene cause LCA, leading to progressive vision loss and eventually blindness.
Mechanism of Action
Resamirigene Bilparvovec works by using a modified, harmless virus (Adeno-associated virus AAV) to deliver a normal copy of the RPE65 gene to retinal cells. The virus is injected directly into the retina where it enters the cells and delivers the gene. This allows the cells to produce the necessary protein for vision, restoring the patient's ability to respond to light.
Clinical Trials and Approval
The effectiveness of Resamirigene Bilparvovec was established in a clinical trial involving patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. The trial demonstrated significant improvement in the ability to navigate in low light, a common problem for people with LCA.
In December 2017, the FDA approved Resamirigene Bilparvovec, making it the first gene therapy for a genetic disease in the U.S. The European Medicines Agency (EMA) granted marketing authorization for the therapy in November 2018.
Side Effects
Like all medicines, Resamirigene Bilparvovec can cause side effects, although not everybody gets them. The most common side effects include eye redness, cataract, increased intraocular pressure, and retinal tear.
See Also
- Gene Therapy
- Leber's congenital amaurosis
- Food and Drug Administration
- Adeno-associated virus
- European Medicines Agency
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD